PharmaJet has signed a deal with Scancell Holdings to use its needle-free delivery system, Stratis, to deliver Scancell’s advanced melanoma DNA vaccine (Immunobody SCIB1/iSCIB1+).
Under the agreement, PharmaJet is set to receive development and regulatory milestone payments, as well as royalties on net sales if the product is commercialised. Scancell is responsible for the clinical and regulatory development, as well as the commercialisation of the combined product.
Go deeper with GlobalData
Needle-free technology works by propelling a small jet of liquid or powder at high speed through a microscopic orifice causing it to penetrate the skin for subcutaneous, intra-dermal, or intramuscular administration. Stratis delivers a fixed dose of 0.5ml of intramuscular and subcutaneous injections in less than one-tenth of a second, according to the company website.
According to the companies, Stratis has demonstrated the ability to facilitate effective updates of Scancell’s DNA melanoma vaccine. The vaccine is delivered to the body’s cells, where it uses cellular processes to express the target antigen, triggering a strong anti-tumour response. So far, 60 patients across 15 clinical sites have successfully received a total of 171 doses of SCIB1/iSCIB1 using the Stratis delivery system.
Scancell’s CEO Lindy Durrant said: “Securing long-term supply for the PharmaJet Stratis Needle-free Injection System is important to allow clinical and commercial development of iSCIB1+. We are pleased that PharmaJet delivery works effectively with the SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunisation for patients.”
According to GlobalData analysis, Colorado-headquartered PharmaJet is a key player involved in the active development of needle-free injections. In 2020, the company was awarded $9.6m from the Joint Science and Technology Office of the US Defense Threat Reduction Agency (DTRA) to fund the use of PharmaJet’s needle-free devices.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNeedle-free delivery mechanisms are increasing in popularity, offering an alternative to traditional needles which can require training to administer. Crossject – another key player in the space – secured €6.9m in funding from the French Government in July 2024. The company will use the funds to advance the development of its needle-free allergic reaction treatment ZENEO Epinefrine.
